Venus Medtech (Hangzhou) Inc. (VMTHF)

Market Cap	107.35M -62.5%
Revenue (ttm)	59.64M -8.4%
Net Income	-89.70M
EPS	-0.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,000
Average Volume	24,499
Open	0.4219
Previous Close	0.2681
Day's Range	0.4219 - 0.4219
52-Week Range	0.1963 - 0.5196
Beta	1.11
RSI	16.10
Earnings Date	Mar 31, 2026

About Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Ve...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2009
• Employees: 605
• Stock Exchange: OTCMKTS
• Ticker Symbol: VMTHF

Financial Performance

In 2024, Venus Medtech (Hangzhou)'s revenue was 470.83 million, a decrease of -4.18% compared to the previous year's 491.37 million. Losses were -714.31 million, 1.50% more than in 2023.

Financial numbers in CNY